Findings Support Bisphosphonate Use in Men With Osteoporosis

Share this content:
Findings Support Bisphosphonate Use in Men With Osteoporosis
Findings Support Bisphosphonate Use in Men With Osteoporosis

TUESDAY, Nov. 15, 2016 (HealthDay News) -- Bisphosphonates reduce the risk of vertebral, and possibly nonvertebral, fractures for men with osteoporosis, according to a review and meta-analysis published online Nov. 7 in the Journal of the American Geriatrics Society.

Smita Nayak, M.D., from the Swedish Medical Center in Seattle, and Susan L. Greenspan, M.D., from the University of Pittsburgh, conducted a systematic literature review to identify clinical trials that evaluated the efficacy of osteoporosis treatment for adult men, as well as reported fracture outcomes.

The researchers identified 24 eligible articles reporting results for 22 studies (including 4,868 male participants). Analysis showed significantly lower risk of vertebral fractures with alendronate (relative risk [RR], 0.328; 95 percent confidence interval (CI), 0.155 to 0.692) and risedronate (RR, 0.428; 95 percent CI, 0.245 to 0.746), but not with calcitonin (RR, 0.272; 95 percent CI, 0.046 to 1.608) or denosumab (RR, 0.256; 95 percent CI, 0.029 to 2.238), compared to controls. Meta-analyses showed that, as a treatment category, bisphosphonates demonstrated significantly lower risk of vertebral fractures (RR, 0.368; 95 percent CI, 0.252 to 0.537) and nonvertebral fractures (RR, 0.604; 95 percent CI, 0.404 to 0.904) versus controls. However, in sensitivity analysis, the finding that bisphosphonates significantly reduce nonvertebral fracture risk was not upheld.

"These findings support the use of bisphosphonates to reduce vertebral and possibly nonvertebral fracture risk for men with osteoporosis," the authors write.

One author disclosed financial ties to Merck.

Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions

More in Home

Post-C-Section Cephalexin, Metronidazole Cuts SSI Rate

Post-C-Section Cephalexin, Metronidazole Cuts SSI Rate

Post-op course reduces rate of surgical site infection within 30 days of C-section among obese women

Multicomponent Intervention Linked to Greater Drop in BP

Multicomponent Intervention Linked to Greater Drop in BP

Intervention beneficial over 18 months for low-income adults in Argentina with uncontrolled HTN

Total of 0.21 Years Lost Due to Opioid-Related Poisoning Deaths

Total of 0.21 Years Lost Due to Opioid-Related ...

Drug-related poisoning deaths up from 2000 to 2015, with most of the increase due to opioid deaths

is free, fast, and customized just for you!

Already a member?

Sign In Now »